[go: up one dir, main page]

EA202091888A1 - VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR - Google Patents

VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR

Info

Publication number
EA202091888A1
EA202091888A1 EA202091888A EA202091888A EA202091888A1 EA 202091888 A1 EA202091888 A1 EA 202091888A1 EA 202091888 A EA202091888 A EA 202091888A EA 202091888 A EA202091888 A EA 202091888A EA 202091888 A1 EA202091888 A1 EA 202091888A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nkg2d receptor
antibody domains
variable antibody
nkg2d
domains targeted
Prior art date
Application number
EA202091888A
Other languages
Russian (ru)
Inventor
Грегори П. Чан
Энн Ф. Чеунг
Ася ГРИНБЕРГ
Уилльям Хани
Брэдли М. Лунде
Бьянка Принц
Original Assignee
Драгонфлай Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Драгонфлай Терапьютикс, Инк. filed Critical Драгонфлай Терапьютикс, Инк.
Priority claimed from PCT/US2019/017330 external-priority patent/WO2019157366A1/en
Publication of EA202091888A1 publication Critical patent/EA202091888A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Описаны вариабельные домены тяжелой цепи антитела, которые могут быть спарены с вариабельными доменами легкой цепи антитела с образованием антигенсвязывающего участка, нацеленного на рецептор NKG2D на поверхности естественных клеток-киллеров. Также описаны белки, содержащие участок, связывающий антиген NKG2D, фармацевтические композиции, содержащие их, и способы лечения, в том числе лечения рака.The variable domains of the heavy chain of an antibody are described that can be paired with the variable domains of the light chain of an antibody to form an antigen-binding site that targets the NKG2D receptor on the surface of natural killer cells. Also described are proteins containing an NKG2D antigen binding site, pharmaceutical compositions containing them, and methods of treatment, including cancer treatment.

EA202091888A 2018-08-08 2019-02-08 VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR EA202091888A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862716259P 2018-08-08 2018-08-08
PCT/US2019/017330 WO2019157366A1 (en) 2018-02-08 2019-02-08 Antibody variable domains targeting the nkg2d receptor

Publications (1)

Publication Number Publication Date
EA202091888A1 true EA202091888A1 (en) 2020-10-23

Family

ID=69413631

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202091888A EA202091888A1 (en) 2018-08-08 2019-02-08 VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
EA202190453A EA202190453A1 (en) 2018-08-08 2019-08-07 POLYSPECIFIC BINDING PROTEINS THAT BIND TO HER2, NKG2D AND CD16 AND METHODS OF THEIR APPLICATION

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202190453A EA202190453A1 (en) 2018-08-08 2019-08-07 POLYSPECIFIC BINDING PROTEINS THAT BIND TO HER2, NKG2D AND CD16 AND METHODS OF THEIR APPLICATION

Country Status (19)

Country Link
US (2) US12275791B2 (en)
EP (2) EP4249067A3 (en)
JP (1) JP7431394B2 (en)
KR (1) KR102645411B1 (en)
CN (1) CN112770769B (en)
AU (1) AU2019318425B2 (en)
BR (1) BR112021002213A2 (en)
CA (1) CA3108794A1 (en)
DK (1) DK3833386T5 (en)
EA (2) EA202091888A1 (en)
ES (1) ES2954851T3 (en)
FI (1) FI3833386T3 (en)
IL (1) IL280656B2 (en)
MX (1) MX2021001508A (en)
MY (1) MY201987A (en)
SA (1) SA521421188B1 (en)
SG (1) SG11202101276QA (en)
WO (1) WO2020033587A1 (en)
ZA (1) ZA202100916B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190118172A (en) 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. Multispecific Binding Proteins for Activation of Natural Killer Cells and Their Therapeutic Uses in Cancer Treatment
JP7685821B2 (en) 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Proteins that bind to Her2, NKG2D and CD16
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN-BINDING CONSTRUCTS AND GENERALLY MODIFIED T-CELLS FOR THE TREATMENT OF DISEASES
DK3749346T3 (en) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc ANTIBODY VARIABLE DOMAIN COMBINATIONS TARGETING THE NKG2D RECEPTOR
CN112040971A (en) 2018-02-08 2020-12-04 蜻蜓疗法股份有限公司 Combination cancer therapy involving multispecific binding proteins that activate natural killer cells
TW201942134A (en) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
JP7443240B2 (en) 2018-03-27 2024-03-05 サイフォス、バイオサイエンシズ、インコーポレイテッド Modified A1-A2 domains of non-natural NKG2D ligands that bind to non-natural NKG2D receptors
CN112955465A (en) 2018-07-03 2021-06-11 马伦戈治疗公司 anti-TCR antibody molecules and uses thereof
EA202091888A1 (en) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
KR20250112921A (en) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Proteins binding nkg2d, cd16 and a tumor-associated antigen
CN114026122B (en) 2019-02-21 2024-12-31 马伦戈治疗公司 Multifunctional molecules that bind to T cell-associated cancer cells and their uses
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
MX2022002524A (en) * 2019-08-30 2022-06-24 Dragonfly Therapeutics Inc PHARMACEUTICAL FORMULATIONS AND DOSING REGIMES FOR MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D AND CD16 FOR THE TREATMENT OF CANCER.
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2021267953A1 (en) * 2020-05-04 2022-11-17 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and clec12a
AR122132A1 (en) * 2020-05-21 2022-08-17 Merus Nv METHODS AND MEANS FOR PRODUCTION OF IG-TYPE MOLECULES
CN117222663A (en) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 Methods of treating cancer using multispecific binding proteins that bind NKG2D, CD16, and tumor-associated antigens
CN116023501A (en) * 2021-10-25 2023-04-28 三生国健药业（上海）股份有限公司 An anti-HER2 immunotoxin molecule, its preparation method and application
EP4476263A4 (en) * 2022-02-09 2026-01-28 Dragonfly Therapeutics Inc Pharmaceutical formulations and therapeutic uses of multispecific binding proteins for binding EGFR, NKG2D and CD16
WO2024081329A1 (en) * 2022-10-12 2024-04-18 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (314)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008854A1 (en) 1987-05-06 1988-11-17 Egbert Oosterwijk Monoclonal antibodies to renal cell carcinoma
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0415929A1 (en) 1988-01-15 1991-03-13 Centocor, Inc. Heteroligating antibodies and therapeutic uses thereof
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
ES2193143T3 (en) 1992-03-05 2003-11-01 Univ Texas USE OF IMMUNOCONJUGADOS FOR THE DIAGNOSIS AND / OR THERAPY OF VASCULARIZA TUMORS.
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69636015T2 (en) 1995-05-03 2007-01-04 Bioenhancementsments Ltd. BIS-SPECIFIC ANTIBODIES IN WHICH THE BINDING ABILITY IS INHERITIZED BY A MEDIUM-SPLITABLE GROUP REVERSIBLE
DE19531346A1 (en) 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Medicines for immunotherapy, containing antibodies that specifically recognize the MHCII antigen of a patient to be treated
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
WO2000023087A1 (en) 1998-10-21 2000-04-27 Sunol Molecular Corporation Polyspecific binding molecules and uses thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CZ20023203A3 (en) 2000-03-24 2003-08-13 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the NKG2D receptor complex
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
US20040115198A1 (en) 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
DE10156482A1 (en) 2001-11-12 2003-05-28 Gundram Jung Bispecific antibody molecule
NZ542784A (en) 2002-08-19 2008-07-31 Astrazeneca Ab Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
DE10261223A1 (en) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Increasing the immune response through substances that influence the function of natural killer cells
AU2004210088A1 (en) 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
AU2004242845B2 (en) 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
KR101325023B1 (en) 2003-07-02 2013-11-04 노보 노르디스크 에이/에스 Compositions and methods for regulating nk cell activity
CN104645327A (en) 2003-07-24 2015-05-27 依奈特制药公司 Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
NZ546173A (en) 2003-10-16 2009-04-30 Micromet Ag Multispecific deimmunized CD3-binders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
SI1716178T1 (en) 2004-02-16 2010-11-30 Micromet Ag Less immunogenic binding molecules
JP2008502597A (en) 2004-04-30 2008-01-31 イネイト・ファーマ Compositions and methods for treating immunoproliferative disorders such as NK-type LDGL
KR20070042967A (en) 2004-07-16 2007-04-24 마이크로메트 에이지 Expression Enhanced Polypeptides
KR20180091967A (en) 2004-07-22 2018-08-16 제넨테크, 인크. Her2 antibody composition
MX2007003910A (en) 2004-10-01 2007-06-07 Avidex Ltd T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents.
DOP2006000029A (en) 2005-02-07 2006-08-15 Genentech Inc ANTIBODY VARIANTS AND USES THEREOF. (VARIATIONS OF AN ANTIBODY AND USES OF THE SAME)
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc HERCEPTIN® adjuvant therapy
US20070071759A1 (en) 2005-06-29 2007-03-29 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
EP1928495A2 (en) 2005-08-19 2008-06-11 Cerus Corporation Antibody-mediated enhancement of immune response
PE20071101A1 (en) 2005-08-31 2007-12-21 Amgen Inc POLYPEPTIDES AND ANTIBODIES
DK1940881T3 (en) 2005-10-11 2017-02-20 Amgen Res Munich Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
EP2322557B1 (en) 2005-10-14 2017-08-30 Innate Pharma Compositions and methods for treating proliferative disorders
JP2009513608A (en) 2005-10-28 2009-04-02 ノボ・ノルデイスク・エー／エス Fusion protein that binds effector lymphocytes to target cells
US20090226466A1 (en) 2005-11-03 2009-09-10 Sherman Fong Therapeutic anti-her2 antibody fusion polypeptides
JP2009514528A (en) 2005-11-03 2009-04-09 フレッド ハッチンソン キャンサー リサーチ センター Negative immunomodulation method of immune response by NKG2D positive CD4 + cells
CA2633594C (en) 2005-12-16 2021-10-26 Micromet Ag Means and methods for the treatment of tumorous diseases
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
RU2487888C2 (en) 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Single-chain multivalent binding proteins with effector function
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
EA017203B1 (en) 2006-09-07 2012-10-30 Круселл Холланд Б.В. HUMAN BINDING MOLECULES, HOW TO NEUTRALIZE THE H5N1 FLU VIRUS, AND THEIR USE
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
CN101269760B (en) 2007-03-23 2011-11-16 海德堡印刷机械股份公司 Paper delivery drum and perfecting press
CA2687117A1 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
JP2010534469A (en) 2007-07-25 2010-11-11 アストラゼネカ アクチボラグ KDR-directed targeted binding substances and uses thereof
CN103298935A (en) 2007-08-15 2013-09-11 阿穆尼克斯公司 Compositions and methods for improving the performance of biologically active polypeptides
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
CN101855242B (en) 2007-09-14 2014-07-30 阿迪马布有限责任公司 Rationally designed, synthetic antibody libraries and uses therefor
SI2235064T1 (en) 2008-01-07 2016-04-29 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CA2712697A1 (en) 2008-01-22 2009-07-30 Biogen Idec Ma Inc. Ron antibodies and uses thereof
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
CA2737351A1 (en) 2008-09-26 2010-04-01 Wyeth Llc Single chain antibody library design
JP2012508017A (en) 2008-11-07 2012-04-05 ファブラス エルエルシー Anti-DLL4 antibody and use thereof
WO2010080124A2 (en) 2008-12-18 2010-07-15 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
KR20110104032A (en) 2008-12-19 2011-09-21 마크로제닉스, 인크. Covalently Bonded Diabodies and Their Uses
CA2757531A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
WO2010132697A2 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treatment
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
WO2010144295A1 (en) 2009-06-09 2010-12-16 University Of Miami Aptamer-targeted costimulatory ligand aptamer
SG177560A1 (en) 2009-07-06 2012-03-29 Hoffmann La Roche Bi-specific digoxigenin binding antibodies
UY32808A (en) 2009-07-29 2011-02-28 Abbott Lab IMMUNOGLOBULINS AS A DUAL VARIABLE DOMAIN AND USES OF THE SAME
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102597223B (en) 2009-09-11 2017-05-10 宝生物工程株式会社 Method for producing natural killer cells
DE102009045006A1 (en) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 antibodies and their use for immuno-targeting in the treatment of CD33-associated diseases
KR102406407B1 (en) 2009-10-27 2022-06-08 암젠 리서치 (뮌헨) 게엠베하 Dosage regimen for administering a CD19xCD3 bispecific antibody
WO2011057124A1 (en) 2009-11-06 2011-05-12 Transtarget, Inc. Polyclonal bispecific antibody compositions and method of use
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
MX2012007055A (en) 2009-12-18 2012-10-15 Amgen Inc Wise binding agents and epitopes.
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
WO2011085178A1 (en) 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
TWI653333B (en) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 Cross-species specific PSMAxCD3 bispecific single chain antibody
ES2989108T3 (en) 2010-04-20 2024-11-25 Genmab As Proteins containing heterodimeric antibody FC and methods for producing the same
TW201742925A (en) 2010-04-23 2017-12-16 建南德克公司 Production of heteromultimeric proteins
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA2801210C (en) 2010-06-19 2020-07-21 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
DE102010039018B4 (en) 2010-08-06 2013-02-28 Technische Universität Dresden Anti-La antibodies and their use for immuno-targeting
WO2012020096A1 (en) 2010-08-13 2012-02-16 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
RU2013115927A (en) 2010-09-10 2014-10-20 Апексиджен, Инк. ANTIBODIES AGAINST IL-1β AND METHODS OF APPLICATION
UA112062C2 (en) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх CD33-Binding Agent
US20120263722A1 (en) 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CA2817015A1 (en) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
PH12013500974A1 (en) 2010-11-17 2013-07-08 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
CA2830254C (en) 2011-03-16 2019-09-10 Amgen Inc. Fc variants
EP2688909A2 (en) 2011-03-25 2014-01-29 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
JP6400470B2 (en) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド Multispecific Fab fusion proteins and methods of use
WO2012162068A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
WO2012175613A1 (en) 2011-06-21 2012-12-27 Innate Pharma NKp46-MEDIATED NK CELL TUNING
DE102011118022B4 (en) 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antibodies against the prostate-specific stem cell antigen and its use
RU2641256C2 (en) 2011-06-30 2018-01-16 Чугаи Сейяку Кабусики Кайся Heterodimerizated polypeptide
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
MX347829B (en) 2011-07-22 2017-05-15 Affimed Therapeutics Ag Multivalent antigen-binding fv molecule.
WO2013036799A2 (en) 2011-09-09 2013-03-14 Fred Hutchinson Cancer Research Center Methods and compositions involving nkg2d inhibitors and cancer
JP6322411B2 (en) 2011-09-30 2018-05-09 中外製薬株式会社 Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
CN107287660A (en) 2011-09-30 2017-10-24 中外制药株式会社 Ion concentration dependence binding molecule library
HUE033245T2 (en) 2011-12-19 2017-11-28 Synimmune Gmbh Bispecific antibody molecule
AU2013200903B2 (en) 2012-02-08 2015-05-14 Mcure Biosciences Inc. CDIM binding proteins and uses thereof
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9029510B2 (en) 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
CN114163530B (en) 2012-04-20 2025-04-29 美勒斯公司 Methods and means for producing immunoglobulin-like molecules
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
CN107964042B (en) 2012-05-30 2022-04-19 中外制药株式会社 Target tissue specific antigen binding molecules
US11142563B2 (en) 2012-06-14 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified Fc region
CN105050618B (en) 2012-06-21 2018-11-16 索伦托治疗有限公司 Antigen-binding protein that binds to c-Met
RU2639287C2 (en) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Method for selection and obtaining of highly selective and multispecific targeting groups with specified properties, including at least two different binding groups, and their applications
WO2014012085A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
WO2014015175A1 (en) * 2012-07-18 2014-01-23 Massachusetts Institute Of Technology Compositions and methods for modulating brd4 bioactivity
WO2014018572A2 (en) 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
EP3586874A1 (en) 2012-08-14 2020-01-01 IBC Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
SG10201705787VA (en) 2012-09-27 2017-08-30 Merus Nv BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
WO2014079000A1 (en) * 2012-11-21 2014-05-30 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
JP6385357B2 (en) 2012-11-27 2018-09-05 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ Heterologous dimer of antibody heavy chain constant region, CH3 domain mutant pair that induces high-efficiency formation, production method and use thereof
WO2014100490A1 (en) 2012-12-19 2014-06-26 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
EA201500741A1 (en) 2013-01-10 2016-01-29 Генмаб Б.В. HUMAN FG IGG1 OPTIONS AND THEIR APPLICATION
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
SG11201505663YA (en) * 2013-01-24 2015-08-28 Scripps Korea Antibody Inst Protein combination-based fv library, and preparation method therefor
CN104968682A (en) 2013-02-05 2015-10-07 英格玛布股份公司 Bispecific antibodies against CD3[epsilon] and BCMA
HK1218930A1 (en) 2013-02-08 2017-03-17 Abbvie Stemcentrx Llc Novel multispecific constructs
EP2961771B1 (en) 2013-02-26 2020-01-01 Roche Glycart AG Bispecific t cell activating antigen binding molecules specific to cd3 and cea
SG10201705245TA (en) 2013-03-14 2017-07-28 Macrogenics Inc Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA2903576C (en) 2013-03-15 2021-06-08 Nai-Kong V. Cheung High affinity anti-gd2 antibodies
ES2821753T3 (en) 2013-03-15 2021-04-27 Lilly Co Eli Fab and bispecific antibody production procedures
CN111138543B (en) * 2013-03-15 2024-06-11 Xencor股份有限公司 Heterodimer protein
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
US10156574B2 (en) 2013-04-29 2018-12-18 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
AU2014264951A1 (en) 2013-05-10 2015-11-12 Numab Therapeutics AG Bispecific constructs and their use in the treatment of various diseases
WO2014198748A1 (en) 2013-06-11 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
CN105612183A (en) 2013-07-15 2016-05-25 诺和诺德股份有限公司 Antibodies that bind urokinase plasminogen activator
KR20160030936A (en) 2013-07-16 2016-03-21 제넨테크, 인크. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
KR102216088B1 (en) 2013-07-25 2021-02-15 싸이톰스 테라퓨틱스, 인크. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
CA2924252C (en) 2013-09-16 2022-01-04 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions
GB2518221A (en) 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
EP3066130B1 (en) 2013-11-07 2019-05-15 Memorial Sloan-Kettering Cancer Center Anti-wt1/hla bi-specific antibody
DE102013019352A1 (en) 2013-11-13 2015-09-17 Elke Pogge Von Strandmann Tri-specific recombinant antibody derivatives for the treatment of malignant diseases by activating an NK cell-based immune response
WO2015077891A1 (en) 2013-11-27 2015-06-04 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2
SG11201604784XA (en) 2013-12-13 2016-07-28 Genentech Inc Anti-cd33 antibodies and immunoconjugates
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
KR20160099087A (en) 2013-12-20 2016-08-19 에프. 호프만-라 로슈 아게 Bispecific her2 antibodies and methods of use
CN105849124B (en) 2013-12-20 2022-04-12 豪夫迈·罗氏有限公司 Dual specificity antibodies
EP3087185A4 (en) 2013-12-23 2017-09-06 Zymeworks Inc. Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
AU2015206407A1 (en) 2014-01-15 2016-08-18 Zymeworks Inc. Bi-specific CD3 and CD19 antigen-binding constructs
PL3125934T3 (en) 2014-03-05 2020-04-30 Ucl Business Plc. Chimeric antigen receptor (CAR) with antigen binding domains to the T beta cell receptor constant region
KR20160146747A (en) 2014-03-31 2016-12-21 제넨테크, 인크. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US20170022291A1 (en) 2014-04-01 2017-01-26 Adimab, Llc Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
UA117289C2 (en) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг MULTISPECIFIC ANTIBODY
SI3560954T1 (en) 2014-04-03 2021-11-30 Igm Biosciences, Inc. Modified j-chain
US10160812B2 (en) 2014-04-11 2018-12-25 Medimmune, Llc Bispecific HER2 antibodies
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
EP2942629A1 (en) 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
AP2016009586A0 (en) 2014-05-29 2016-11-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
AU2015279321B2 (en) 2014-06-27 2021-03-04 Innate Pharma, S.A. Multispecific antigen binding proteins
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
AU2015279316B2 (en) 2014-06-27 2021-03-04 Innate Pharma Multispecific NKp46 binding proteins
PE20170286A1 (en) 2014-07-01 2017-03-30 Pfizer BISPECIFIC HETERODIMERIC DIACBODIES AND THEIR USES
BR112017001242A2 (en) 2014-07-21 2017-12-05 Novartis Ag cancer treatment using a cd33 chimeric antigen receptor
EP3172237A2 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US9777073B2 (en) 2014-07-21 2017-10-03 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody EpCAM×CD3
WO2016011571A1 (en) 2014-07-21 2016-01-28 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell
JP6390239B2 (en) 2014-07-25 2018-09-19 富士ゼロックス株式会社 Information processing apparatus and program
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
EP3186282A1 (en) 2014-08-28 2017-07-05 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
ES2688035T3 (en) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Universal antigen receptor that expresses immune cells for addressing multiple multiple antigens, procedure for manufacturing it and using it for the treatment of cancer, infections and autoimmune diseases
AU2015342264B2 (en) 2014-11-03 2021-08-12 Merck Patent Gmbh Methods for generating bispecific shark variable antibody domains and use thereof
JP6721590B2 (en) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Multispecific antibody
EP3227311B1 (en) * 2014-12-05 2022-02-02 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
EP3233122A4 (en) 2014-12-17 2018-09-19 Intrexon Corporation Intercalated single-chain variable fragments
JP6709003B2 (en) 2014-12-19 2020-06-10 株式会社カイオム・バイオサイエンス Fusion protein containing three binding domains for 5T4 and CD3
JP6744313B2 (en) 2015-01-02 2020-08-26 ダイアックス コーポレーション Bispecific antibodies to plasma kallikrein and factor XII
BR112017015136A2 (en) * 2015-01-14 2018-01-30 Compass Therapeutics Llc multispecific immunomodulator antigen binding construct polypeptide, multispecific immunomodulator antigen binding construct, conjugate, pharmaceutical composition, method for treating an individual with cancer, method for inhibiting or reducing cancer growth, composition, cell, method of making a polypeptide of multispecific immunomodulatory antigen binding construct, vector or vector set and kit
WO2016122701A1 (en) 2015-01-26 2016-08-04 Macrogenics, Inc. Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof
WO2016134371A2 (en) 2015-02-20 2016-08-25 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
MA41613A (en) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc ANTI-DLL3 CHEMERICAL ANTIGENIC RECEPTORS AND METHODS FOR USING SUCH RECEIVERS
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016142768A1 (en) 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
CN107223135B (en) 2015-03-16 2021-11-02 亥姆霍兹慕尼黑中心-德国环境健康研究中心(Gmbh) Trispecific binding molecules for the treatment of HBV infection and related disorders
WO2016161390A1 (en) 2015-04-03 2016-10-06 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
CN107921090A (en) 2015-04-06 2018-04-17 苏伯多曼有限责任公司 Polypeptides containing de novo binding domains and uses thereof
CA2981851A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
WO2016187220A2 (en) 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
EP3095792A1 (en) 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
WO2016191305A1 (en) 2015-05-22 2016-12-01 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
DK3303394T3 (en) * 2015-05-29 2020-07-06 Agenus Inc ANTI-CTLA-4 ANTIBODIES AND PROCEDURES FOR USE THEREOF
DK3303396T5 (en) 2015-05-29 2024-10-07 Bristol Myers Squibb Co ANTIBODIES AGAINST OX40 AND USES THEREOF
HK1252675A1 (en) 2015-06-12 2019-05-31 Alector Llc Anti-cd33 antibodies and methods of use thereof
JP2018522833A (en) 2015-06-12 2018-08-16 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Chimeric antigen receptor (CAR) constructs and disease treatment with T cells (CAR-T) or NK cells (CAR-NK) expressing CAR constructs
WO2016207273A2 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific antigen binding proteins
EP3313881A1 (en) 2015-06-23 2018-05-02 Innate Pharma Multispecific nk engager proteins
EP3319984A1 (en) 2015-07-06 2018-05-16 UCB Biopharma SPRL Tau-binding antibodies
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
CN108137706A (en) 2015-07-15 2018-06-08 酵活有限公司 Drug-conjugated bispecific antigen-binding constructs
JP2018523471A (en) 2015-07-16 2018-08-23 セレラント セラピューティクス インコーポレイテッド Cysteine substituted immunoglobulin
TW202346349A (en) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
US20180251548A1 (en) 2015-09-14 2018-09-06 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-beta
EP3356403A2 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
KR101851380B1 (en) 2015-10-12 2018-04-23 아주대학교산학협력단 Method to generate CH3 domain mutant pairs of heterodimeric Fc using yeast mating and CH3 domain mutant pairs thereby
CN108431041B (en) 2015-10-29 2022-08-16 艾利妥 anti-SIGLEC-9 antibodies and methods of use thereof
BR112018009129A2 (en) * 2015-11-04 2019-02-26 J. PRICEMAN Saul her2 targeting chimeric antigen receptors
WO2017083545A1 (en) 2015-11-10 2017-05-18 Fred Hutchinson Cancer Research Center Nkg2d decoys
WO2017081190A1 (en) 2015-11-13 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
AU2016383475B2 (en) 2015-12-28 2024-02-22 Innate Pharma Variable regions for NKp46 binding proteins
US20190031785A1 (en) 2016-01-13 2019-01-31 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
ES2847155T3 (en) 2016-01-21 2021-08-02 Novartis Ag Multispecific molecules targeting CLL-1
WO2017142928A1 (en) 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof
WO2017143406A1 (en) 2016-02-26 2017-08-31 Imunexus Pty Ltd Multi-specific molecules
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
CR20180484A (en) 2016-04-15 2019-03-05 Macrogenics Inc NEW B7-H3 UNON MOLECULES, ANTIBODY-DRUG CONJUGATES OF THE SAME AND METHODS OF USE OF THE SAME
BR112018070676A2 (en) 2016-04-15 2019-02-05 Zymeworks Inc multispecific antigen binding constructs that target immunotherapeutic agents
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
MA45255A (en) 2016-06-14 2019-04-17 Xencor Inc BISPECIFIC CONTROL POINT INHIBITORS ANTIBODIES
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN105906722B (en) 2016-06-24 2020-02-07 安徽未名细胞治疗有限公司 Her2 specific chimeric antigen receptor and application thereof
EP3507307A4 (en) 2016-09-01 2020-04-22 Immunomab, Inc. Bispecific antibodies
WO2018071777A1 (en) 2016-10-14 2018-04-19 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
CN110267678A (en) 2016-10-29 2019-09-20 霍夫曼-拉罗奇有限公司 Anti-MIC antibodies and methods of use
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JOP20190134A1 (en) 2016-12-23 2019-06-02 Potenza Therapeutics Inc Anti-neuropilin antigen-binding proteins and methods of use thereof
EP3579866A4 (en) 2017-02-08 2020-12-09 Dragonfly Therapeutics, Inc. HEAVY CHAIN VARIABLE ANTIBODY DOMAINS WITH NKG2D RECEPTOR AIMING
KR20190118172A (en) * 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. Multispecific Binding Proteins for Activation of Natural Killer Cells and Their Therapeutic Uses in Cancer Treatment
JP2020507577A (en) 2017-02-10 2020-03-12 ドラゴンフライ セラピューティクス， インコーポレイテッド Protein binding to PSMA, NKG2D and CD16
EP3579876A4 (en) 2017-02-10 2020-11-18 Dragonfly Therapeutics, Inc. Proteins binding bcma, nkg2d and cd16
CN110891976A (en) 2017-02-20 2020-03-17 蜻蜓疗法股份有限公司 Proteins that bind GD2, NKG2D and CD16
KR20190120781A (en) 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Proteins That Bind to CD123, NKG2D, and CD16
BR112019017277A2 (en) 2017-02-20 2020-04-14 Dragonfly Therapeutics, Inc. binding proteins to cd33, nkg2d and cd16
JP7685821B2 (en) * 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Proteins that bind to Her2, NKG2D and CD16
KR20200130514A (en) 2017-02-27 2020-11-18 드래곤플라이 쎄라퓨틱스, 인크. Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
MX2019013995A (en) 2017-05-23 2020-07-29 Dragonfly Therapeutics Inc A protein binding nkg2d, cd16 and a tumor-associated antigen.
WO2018217947A1 (en) 2017-05-23 2018-11-29 Dragonfly Therapeutics, Inc. A protein binding nkg2d, cd16 and a tumor-associated antigen
BR112019024654A2 (en) 2017-05-23 2020-06-09 Dragonfly Therapeutics Inc binding protein nkg2d, cd16 and ror1 or ror2
JP2019014449A (en) 2017-07-10 2019-01-31 トヨタ自動車株式会社 Vehicular power transmission device
AU2018309712A1 (en) 2017-07-31 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and FLT3
EP3882270A3 (en) 2017-08-16 2021-12-01 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
KR20200038530A (en) 2017-08-23 2020-04-13 드래곤플라이 쎄라퓨틱스, 인크. Proteins that bind NKG2D, CD16 and tumor-associated antigens
MX420258B (en) 2017-09-07 2025-02-10 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
MX2020002880A (en) 2017-09-14 2020-10-01 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1).
DK3749346T3 (en) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc ANTIBODY VARIABLE DOMAIN COMBINATIONS TARGETING THE NKG2D RECEPTOR
CN112040971A (en) 2018-02-08 2020-12-04 蜻蜓疗法股份有限公司 Combination cancer therapy involving multispecific binding proteins that activate natural killer cells
TW201942134A (en) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
PE20211224A1 (en) 2018-02-20 2021-07-06 Dragonfly Therapeutics Inc VARIABLE ANTIBODY DOMAINS TARGETING CD33 AND ITS USES
EP3774921A4 (en) 2018-04-03 2022-01-05 Dragonfly Therapeutics, Inc. Antibody variable domains targeting dll3, and use thereof
WO2019195409A1 (en) 2018-04-03 2019-10-10 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
US20210238290A1 (en) 2018-05-07 2021-08-05 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and p-cadherin
EP3793605A4 (en) 2018-05-16 2022-03-30 Dragonfly Therapeutics, Inc. Protein binding nkg2d, cd16 and a fibroblast activation protein
EA202091977A1 (en) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D AND CD16 AND METHODS OF APPLICATION
KR20250112921A (en) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Proteins binding nkg2d, cd16 and a tumor-associated antigen
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
KR20210044237A (en) 2018-08-08 2021-04-22 드래곤플라이 쎄라퓨틱스, 인크. Proteins that bind to NKG2D, CD16 and tumor-associated antigens
EA202091888A1 (en) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
EP3870598A1 (en) 2018-10-23 2021-09-01 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
KR20210131373A (en) 2019-02-18 2021-11-02 커리어 테라퓨틱스, 인코포레이티드. Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class I-like protein (OMCP) and tumor-specific binding partners
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
AR119393A1 (en) 2019-07-15 2021-12-15 Hoffmann La Roche ANTIBODIES THAT BIND NKG2D
MX2022002524A (en) 2019-08-30 2022-06-24 Dragonfly Therapeutics Inc PHARMACEUTICAL FORMULATIONS AND DOSING REGIMES FOR MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D AND CD16 FOR THE TREATMENT OF CANCER.
AR120222A1 (en) 2019-10-15 2022-02-02 Dragonfly Therapeutics Inc ANTIBODIES DIRECTED TO FLT3 AND USE THEREOF
AU2020368163A1 (en) 2019-10-15 2022-04-28 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and FLT3
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and clec12a
AU2021267023A1 (en) 2020-05-06 2022-12-01 Dragonfly Therapeutics, Inc. Antibodies targeting CLEC12A and use thereof
IL300249A (en) 2020-08-05 2023-03-01 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and egfr
IL300246A (en) 2020-08-05 2023-03-01 Dragonfly Therapeutics Inc Antibodies targeting egfr and use thereof
CN117222663A (en) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 Methods of treating cancer using multispecific binding proteins that bind NKG2D, CD16, and tumor-associated antigens
PE20241584A1 (en) 2021-09-29 2024-08-01 Dragonfly Therapeutics Inc PROTEINS THAT BIND TO NKG2D, CD16 AND BAFF-R
CN118317975A (en) 2021-09-29 2024-07-09 蜻蜓治疗公司 Antibodies targeting BAFF-R and uses thereof
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
EP4476263A4 (en) 2022-02-09 2026-01-28 Dragonfly Therapeutics Inc Pharmaceutical formulations and therapeutic uses of multispecific binding proteins for binding EGFR, NKG2D and CD16
US20230416402A1 (en) 2022-03-03 2023-12-28 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2

Also Published As

Publication number Publication date
IL280656B1 (en) 2023-11-01
CN112770769B (en) 2024-07-12
KR102645411B1 (en) 2024-03-11
DK3833386T5 (en) 2024-08-19
BR112021002213A2 (en) 2021-07-20
JP7431394B2 (en) 2024-02-15
SG11202101276QA (en) 2021-03-30
DK3833386T3 (en) 2023-09-04
EP4249067A2 (en) 2023-09-27
ZA202100916B (en) 2024-08-28
MX2021001508A (en) 2021-07-02
CA3108794A1 (en) 2020-02-13
US20250206827A1 (en) 2025-06-26
CN112770769A (en) 2021-05-07
EP4249067A3 (en) 2023-11-22
EP3833386A4 (en) 2022-07-06
SA521421188B1 (en) 2024-07-25
WO2020033587A1 (en) 2020-02-13
AU2019318425B2 (en) 2024-02-29
JP2021533161A (en) 2021-12-02
ES2954851T3 (en) 2023-11-27
EA202190453A1 (en) 2021-06-10
US12275791B2 (en) 2025-04-15
IL280656B2 (en) 2024-03-01
EP3833386A1 (en) 2021-06-16
MY201987A (en) 2024-03-27
IL280656A (en) 2021-03-25
US20210198369A1 (en) 2021-07-01
EP3833386B1 (en) 2023-06-14
FI3833386T3 (en) 2023-08-28
AU2019318425A1 (en) 2021-03-04
KR20210042121A (en) 2021-04-16

Similar Documents

Publication Publication Date Title
EA202091888A1 (en) VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
MX2020008336A (en) VARIABLE DOMAINS OF ANTIBODIES TARGETING THE NKG2D RECEPTOR.
EA202091976A1 (en) VARIABLE ANTIBODY DOMAINS TARGETING CD33 AND THEIR APPLICATION
EA202092907A1 (en) MULTI-SPECIFIC BINDING PROTEINS AND THEIR IMPROVEMENTS
EA202092668A1 (en) ANTIBODIES TO IL-11
EA202090812A1 (en) NEW BISPECIFIC POLYPEPTIDE COMPLEXES
EA202092945A1 (en) DIFFERENT ANTIGEN BINDING DOMAINS, NEW PLATFORMS AND OTHER IMPROVEMENTS FOR CELL THERAPY
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
EA202190468A1 (en) MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16 AND METHODS OF THEIR APPLICATION
MX2023001556A (en) Antibodies targeting egfr and use thereof.
EA202191785A1 (en) ANTIBODIES TO CTLA4 AND METHODS OF THEIR APPLICATION
EA202090387A1 (en) PROTEINS BINDING NKG2D, CD16 AND FLT3
EA201990183A1 (en) Adenovirus Armed with B-Specific T-Cell Activator (BITE)
EA201892440A1 (en) ANTIBODIES TO TL1A AND THEIR APPLICATIONS
PE20140673A1 (en) NEW MODULATORS AND METHODS FOR THEIR USE
JOP20200343A1 (en) Anti-steap1 antigen-binding protein
MX2022004291A (en) ANTIBODIES DIRECTED TO FMS-RELATED TYROSINE KINASE 3 (FLT3) AND USE THEREOF.
EA201991729A1 (en) ANTIBODIES TO TGF-BETA AND THEIR APPLICATION
WO2021226163A3 (en) Antibodies targeting clec12a and use thereof
EA201791691A1 (en) SINGLE-DOMAIN ANTIBODIES DIRECTED TO CD1d
EA202192810A1 (en) ANTIBODIES TO PcrV THAT BIND PcrV, COMPOSITIONS CONTAINING ANTIBODIES TO PcrV AND METHODS OF THEIR APPLICATION
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
EA201992460A1 (en) BTLA ANTIBODY ANTIBODIES AND THEIR APPLICATION
EA202191656A1 (en) ANTI-IL-36 ANTIBODIES AND METHODS OF THEIR APPLICATION
MX2016011177A (en) Antibodies to matrix metalloproteinase 9 and methods of use thereof.